-

Groupe Berkem Announces Coverage of Its Stock by Berenberg and TP ICAP

BLANQUEFORT, France--(BUSINESS WIRE)--Regulatory News:

Groupe Berkem (Paris:ALKEM), a leading player in bio-based chemicals (ISIN: FR00140069V2 – Ticker: ALKEM) is pleased to announce the initiation of coverage of its stock by Berenberg and TP ICAP.

Berenberg initiated the coverage of the stock with a Buy recommendation in its report "A bio-based earnings boost".

The coverage of Groupe Berkem stock has also been initiated by TP ICAP, following the release of the report "Les ingredients du succès", which recommends buying the stock.

Next financial publication:

2021 annual results and 2022 first-quarter revenue: April 21, 2022 (after market)

ABOUT GROUPE BERKEM

Founded in 1993 by Olivier Fahy, Chairman and Chief Executive Officer, Groupe Berkem is a leading force in the bio-based chemicals market. Its mission is to advance the environmental transition of companies producing the chemicals used in everyday lives (cosmetics, food and beverages, construction, public hygiene, etc.). By harnessing its expertise in both plant extraction and innovative formulations, Groupe Berkem has developed bio-based boosters—unique high-quality bio-based solutions augmenting the performance of synthetic molecules. Groupe Berkem achieved a revenue of €41 million and an EBITDA margin close to 19% in 2020. The Group has almost 165 employees working at its head office (Blanquefort, Gironde) and three production facilities in Gardonne (Dordogne), La Teste-de-Buch (Gironde), and Chartres (Eure-et-Loir). www.groupeberkem.com

Contacts

Groupe Berkem
Olivier Fahy, Chief Executive Officer
Anthony Labrugnas, Chief Financial Officer
Tel.: +33 (0)5 64 31 06 60
berkem@berkem.com

NewCap
Investor Relations
Mathilde Bohin / Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94
Berkem@newcap.eu

NewCap
Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94
Berkem@newcap.eu

Groupe Berkem

BOURSE:ALKEM

Release Versions

Contacts

Groupe Berkem
Olivier Fahy, Chief Executive Officer
Anthony Labrugnas, Chief Financial Officer
Tel.: +33 (0)5 64 31 06 60
berkem@berkem.com

NewCap
Investor Relations
Mathilde Bohin / Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94
Berkem@newcap.eu

NewCap
Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94
Berkem@newcap.eu

More News From Groupe Berkem

Result of the Simplified Tender Offer on Groupe Berkem Shares

BLANQUEFORT, France--(BUSINESS WIRE)--Regulatory News: Groupe Berkem (ISIN code: FR00140069V2 - mnemonic: ALKEM) (the “Company”), a leading player in plant-based chemistry, announces that the Autorité des marchés financiers (AMF) has today published the final result of the simplified tender offer on Groupe Berkem shares (the “Offer”) initiated by Kenerzeo (the “Offeror”). At the close of the Offer, opened from December 9, 2024, to December 20, 2024 included, Kenerzeo individually holds a total...

Groupe Berkem Launches RECELLCL'IN®, Its New Active Ingredient Dedicated to the Cosmetic Market

BLANQUEFORT, France--(BUSINESS WIRE)--Regulatory News: Groupe Berkem (Paris:ALKEM), a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), today announced the launch of RECELLCL'IN®, a new active ingredient for the beauty industry. Marlène De Matos, Groupe Berkem's Active Ingredient Development & Innovation R&D Manager, stated: “For this product launch, we drew the power of polyphenols from the heart of passiflora, to turn a traditionally used plant into an i...

Groupe Berkem Announces Its Revenue of €40.4 Million as of September 30, 2024

BLANQUEFORT, France--(BUSINESS WIRE)--Regulatory News: Groupe Berkem, a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), announces its revenue as of September 30, 2024, and provides an update on its recent activity. 2024 THIRD-QUARTER REVENUE As of September 30, 2024, Groupe Berkem’s revenue for the first nine months of 2024 reached €40.4 million, against €39.9 million over the same period in 2023, i.e. an increase of +1.2%. Repartition of revenue per business ar...
Back to Newsroom